Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer A cell-penetrating and RNA binding antibody forms noncovalent complexes with an immunogenic RNA to target tumors and achieve antitumor efficacy.

🎉 So proud of my wife
Natasha Pinto Medici on her latest co–first author paper in @ScienceTransMed!
🚀 Her team introduces TMAB3 — a tumor-targeted, RNA-binding antibody that delivers RNA directly into tumors after systemic injection.
www.science.org/doi/10.1126/...

Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibition Despite the availability of RAS inhibitors and the dependence of >90% of pancreatic ductal adenocarcinomas (PDAC) on oncogenic KRAS mutations, resistance to KRAS inhibition remains a serious obstacle....

Way to go, @xiangyuge.bsky.social, for a fantastic talk on how #PI3K governs resistance to #KRAS inhibition in #PancreaticCancer cells @faseborg.bsky.social Protein Phosphorylation! @yalepathology.bsky.social @yalecancer.bsky.social. Check out her preprint: www.biorxiv.org/content/10.1...

PI3K takes the spotlight when KRAS is inhibited in PDAC. Fantastic preprint from @xiangyuge.bsky.social now up!

🔁 Check out our new preprint exploring how dietary fats influence pancreatic cancer progression through ferroptosis sensitivity! 🦠🔥 In our model, MUFAs promote tumorigenesis, while PUFAs show protective effects. Read more here 📄👇 #CancerResearch #Ferroptosis #LipidMetabolism #bioRxiv”